FDA approval of a Haemophilus b Conjugate Vaccine combined by reconstitution with an acellular pertussis vaccine

[회의록: 제2회 일본-미국 반코마이신 포럼(토론)]

Published on
Journal: Morbidity and Mortality Weekly Report
[저자] Centers for Disease Control and Prevention (CDC)
[Category] 백일해, 파상풍,
Pubmed URL    DOI URL    
[Source] pubmed

On September 27, 1996, the Food and Drug Administration (FDA) licensed a Haemophilus b Conjugate Vaccine (ActHIB) combined by reconstitution with diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) (Tripedia) for use as the fourth dose in the childhood vaccination series. This combination vaccine will be sold under the trade name TriHIBit. On July 31, 1996, Tripedia was licensed for the initial four doses of the diphtheria, tetanus, and pertussis vaccination series. TriHIBit is the first vaccine to be licensed in the United States that combines DTaP with a Haemophilus b Conjugate Vaccine.

All Keywords